Clinical Trials Sponsored by Brixton Health

Total 53250 results

Bristol-Myers Squibb

Active, not recruiting

A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence Therapy (LIST)

Lung Cancer

France
Bristol-Myers Squibb

Active, not recruiting

A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy (VALOR-HCM)

HOCM, Hypertrophic Obstructive Cardiomyopathy

United States
Bristol-Myers Squibb

Completed

A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus

Lupus Erythematosus, Cutaneous

Germany
Bristol-Myers Squibb

Completed

Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (CheckMate 714)

Head and Neck Cancer

United States, Brazil, Italy, South Africa, Spain, Canada, Argentina, Belgium, Chile, Czechia, Finland, France, Ireland, Mexico, Netherlands, Norway, Romania, Russian Federation, Sweden, Turkey, United Kingdom
Bristol-Myers Squibb

Completed

A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab

Cancer

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Metabolism and Excretion of BMS-986369 in Healthy Male Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study to Assess Relative Bioavailability of Branebrutinib, From a Tablet Formulation to the Capsule Formulation, the Effect of Food on the Bioavailability of Branebrutinib From a Tablet Formulation, and the Safety and Drug Levels of Branebrutinib From a Tablet Formulation in Healthy Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Drug Levels of Cendakimab Delivered Subcutaneously in Healthy Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, and Drug Levels of MYK-224 Administered in Single and Multiple Doses in Healthy Adult Japanese Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

Chronic Phase Chronic Myeloid Leukemia

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Drug Levels of [14C]CC-99677 in Healthy Male Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Effect of Activated Charcoal With Sorbitol on the Single-dose of Mavacamten in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Active, not recruiting

A Post-Authorization, Long-term Study of Ozanimod Real-world Safety (ORION)

Multiple Sclerosis, Relapsing-Remitting

United States
Bristol-Myers Squibb

Completed

An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe Psoriasis

Psoriasis

Japan
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer (CHECKMATE 920)

Renal Cell Carcinoma

United States
Bristol-Myers Squibb

Completed

A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed Conditions

Healthy Participants

United States
Bristol-Myers Squibb

Terminated

An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis

Lupus Nephritis

United States, Taiwan, Spain, United Kingdom, Netherlands, Germany, China, Australia, Belgium, Mexico, Korea, Republic of, Czechia, Russian Federation, Israel, Canada, Italy
Bristol-Myers Squibb

Completed

A Study of Overall Survival in Participants With Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal Cancer (mCRC)

United States
Bristol-Myers Squibb

Completed

Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma (CheckMate 066)

Melanoma

Canada, Australia, Germany, Italy, Poland, France, Denmark, Argentina, Chile, Spain, Norway, Israel, Sweden, Mexico, Greece, Finland
Bristol-Myers Squibb

Completed

A Study of Adjuvant Melanoma Stakeholder Treatment Preferences

Melanoma

Australia
Bristol-Myers Squibb

Completed

Risk Factors and Outcomes of Immune-Mediated Encephalitis Following Exposure to Nivolumab

Encephalitis

United States
Bristol-Myers Squibb

Withdrawn

Study to Describe Risk of Bleeding in Patients Depending on the Different Anticoagulant Therapy They Are on for Atrial Fibrillation (AF)

Non-valvular Atrial Fibrillation

United States
Bristol-Myers Squibb

Completed

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Melanoma

France, Canada, United States, Germany, Australia, Russian Federation, Spain, Italy, Netherlands, Poland, Denmark, Israel, United Kingdom
Bristol-Myers Squibb

Completed

Treatment Patterns and Outcomes in Participants With Advanced Melanoma in Germany Using a German Database

Advanced Melanoma

Germany
Bristol-Myers Squibb

Completed

Study of BMS-986158 in Subjects With Select Advanced Cancers (BET)

Advanced Tumors

United States, France, Australia, Spain, Canada
Bristol-Myers Squibb

Active, not recruiting

A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database (DANBIO)

Rheumatoid Arthritis (RA) | Psoriatic Arthritis (PsA)

United States
Bristol-Myers Squibb

Completed

Measuring the Treatment Preferences of Participants in Japan With Moderate-to-Severe Psoriasis (PsO) Using Discrete Choice Experiment (DCE)

Psoriasis

United States
Bristol-Myers Squibb

Completed

A Study of Treatment Patterns and Clinical Outcomes of Psoriasis in Japan

Psoriasis

Japan
Bristol-Myers Squibb

Completed

Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986278 in Healthy Male Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

A Study Measuring the Effectiveness of BMS-986256 Combined With Oral Contraceptive in Healthy Female Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study Assessing the Drug Levels, Drug Effects, and Safety of BMS-986322 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Active, not recruiting

Real-Life Effectiveness and Safety in Participants With Advanced/Metastatic Renal Cell Carcinoma Starting 1st Line Nivolumab and Ipilimumab Combination Therapy or Nivolumab Monotherapy After Prior Therapy

Renal Cell Carcinoma

Germany
Bristol-Myers Squibb

Completed

A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom

Esophageal Squamous Cell Carcinoma

United Kingdom
Bristol-Myers Squibb

Terminated

An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed

Advanced Cancer

United States
Bristol-Myers Squibb

Completed

Study in Patients With Unresectable And Metastatic Melanoma: The Optimize Study

Melanoma

United States
Bristol-Myers Squibb

Completed

APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study

Anticoagulation

France
Bristol-Myers Squibb

Completed

A Study to Determine the Risk of Cancer in Rheumatoid Arthritis (RA) Patients Who Use Abatacept and Other Biologic Agents

Rheumatoid Arthritis

United States
Bristol-Myers Squibb

No longer available

Expanded Access for Anti-IL8
Bristol-Myers Squibb

Completed

A Study to Assess the Effect of Itraconazole, Phenytoin and Gemfibrozil on the Drug Levels of BMS-986166 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study to Assess the Levels in Blood Plasma of BMS-986278 in Healthy Participants Following Administration of Tablets, With or Without Food, and in the Presence of an Antacid (Esomeprazole)

Healthy Participants

United States
Bristol-Myers Squibb

Completed

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Unresectable or Metastatic Melanoma

United States, Germany, Italy, United Kingdom, Canada, Denmark, Netherlands, Spain, Belgium, France, Switzerland, Israel, Austria, Brazil
Bristol-Myers Squibb

Withdrawn

Study to Evaluate the Effect of Rifampin on the Drug Levels in Blood and Safety of BMS-986235 in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Active, not recruiting

Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab

Lymphoma

United States
Bristol-Myers Squibb

Completed

Relative Levels of BMS-986036 in Blood Plasma in Healthy, Overweight, and Obese Participants Following Subcutaneous Administration Via Auto-injector Versus Pre-filled Syringe

Healthy Participants

United States
Bristol-Myers Squibb

Available

Expanded Access for Apixaban

United States
Bristol-Myers Squibb

Completed

Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma (CheckMate 069)

Metastatic Melanoma | Unresectable Melanoma

United States, France
Bristol-Myers Squibb

Completed

A Study to Evaluate the Drug Levels of Deucravacitinib From Tablets After Oral Administration in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

Study to Assess the Effect of Branebrutinib on the Drug Levels of Rosuvastatin in Healthy Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

Long-term Epidemiological Follow-up of Non-small Cell Lung Cancer in Scandinavia (SCAN-LEAF)

Non-Small Cell Lung Cancer
Bristol-Myers Squibb

Completed

Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in Korea

Hepatitis C

Korea, Republic of

3

Subscribe